Literature DB >> 2913186

Assessing methods for causality assessment of suspected adverse drug reactions.

T A Hutchinson1, D A Lane.   

Abstract

Reproducibility and validity as currently defined are inappropriate criteria for the evaluation of methods for causality assessment. Reproducibility leads to suppression rather than resolution of real disagreements and the method used to establish validity relies on the tarnished gold standard of expert opinion. We describe six alternative criteria that attempt to address a potential user's main concerns--the need to know whether to believe the results in general and in a particular case. These criteria focus on the internal structure of a method rather than its output. When we assessed the published methods by these criteria most of the methods failed most of the criteria. We believe that the problem and its solution lie at a fundamental level--real understanding of the true nature of causality assessment, which we suggest is an inherently subjective evaluation based on the multiple uncertainties that an assessor has about a case and not an objective attribute of the drug-event connection that can be determined from unambiguous evidence elicited in response to "operational questions".

Mesh:

Year:  1989        PMID: 2913186     DOI: 10.1016/0895-4356(89)90020-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  17 in total

1.  Agreement of expert judgment in causality assessment of adverse drug reactions.

Authors:  Yannick Arimone; Bernard Bégaud; Ghada Miremont-Salamé; Annie Fourrier-Réglat; Nicholas Moore; Mathieu Molimard; Françoise Haramburu
Journal:  Eur J Clin Pharmacol       Date:  2005-04-13       Impact factor: 2.953

Review 2.  Methods for causality assessment of adverse drug reactions: a systematic review.

Authors:  Taofikat B Agbabiaka; Jelena Savović; Edzard Ernst
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions.

Authors:  Yannick Arimone; Ghada Miremont-Salamé; Françoise Haramburu; Mathieu Molimard; Nicholas Moore; Annie Fourrier-Réglat; Bernard Bégaud
Journal:  Br J Clin Pharmacol       Date:  2007-08-15       Impact factor: 4.335

4.  Pharmacogenetics and pharmacovigilance.

Authors:  Robert H Howland
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.

Authors:  Saibal Das; Sapan K Behera; Alphienes S Xavier; Srinivas Velupula; Steven A Dkhar; Sandhiya Selvarajan
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

6.  Causal or casual? The role of causality assessment in pharmacovigilance.

Authors:  R H Meyboom; Y A Hekster; A C Egberts; F W Gribnau; I R Edwards
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.606

Review 7.  Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?

Authors:  Gaby Danan; Rolf Teschke
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

8.  Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.

Authors:  Richard T Scheife; Lisa E Hines; Richard D Boyce; Sophie P Chung; Jeremiah D Momper; Christine D Sommer; Darrell R Abernethy; John R Horn; Stephen J Sklar; Samantha K Wong; Gretchen Jones; Mary L Brown; Amy J Grizzle; Susan Comes; Tricia Lee Wilkins; Clarissa Borst; Michael A Wittie; Daniel C Malone
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

Review 9.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.

Authors:  Raúl-J Andrade; Mercedes Robles; Alejandra Fernández-Castañer; Susana López-Ortega; M-Carmen López-Vega; M-Isabel Lucena
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

Review 10.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.